The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
Please provide your email address to receive an email when new articles are posted on . The average health care cost per patient in the indwelling pleural catheter (IPC) group was $40,179 vs. $46,640 ...
DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback